Miragen Therapeutics (NASDAQ:MGEN) released its earnings results on Thursday. The medical research company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.06), Fidelity Earnings reports. The firm had revenue of $0.70 million during the quarter, compared to analyst estimates of $1.67 million. Miragen Therapeutics had a negative net margin of 925.52% and a negative return on equity of 85.50%.
MGEN stock traded down $0.02 during midday trading on Friday, hitting $0.71. The stock had a trading volume of 114,900 shares, compared to its average volume of 213,136. The company has a current ratio of 5.26, a quick ratio of 5.26 and a debt-to-equity ratio of 0.18. The firm has a market cap of $23.64 million, a P/E ratio of -0.65 and a beta of 1.37. Miragen Therapeutics has a 1-year low of $0.63 and a 1-year high of $4.96. The business has a fifty day moving average price of $0.79 and a two-hundred day moving average price of $1.73.
Several research firms recently issued reports on MGEN. HC Wainwright began coverage on shares of Miragen Therapeutics in a report on Monday, August 19th. They issued a “buy” rating and a $3.00 target price on the stock. Zacks Investment Research upgraded shares of Miragen Therapeutics from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a report on Wednesday, October 30th. Finally, ValuEngine upgraded shares of Miragen Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $11.56.
Miragen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous, ocular, and idiopathic pulmonary fibrosis; and MRG-110, an inhibitor of miR-92, a microRNA expressed in endothelial cells for the treatment of heart failure, as well as surgical incisions in high risk populations, severe lacerations, and severe burns in the United States and Japan.
Recommended Story: Does the Step Transaction Doctrine Affect a Backdoor Roth IRA?
Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.